Last 10 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -5.08 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | 1314.06 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Aspire Biopharma Holdings, Inc.'s operating margin was -59015.8% in Q3 2025.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | 45.5% | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | -59015.8% | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | -95337.1% | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | -1.1% | -1.9% | -0.8% | -0.3% | -0.4% |
| — | — | — | — | — | — | -141.8% | — | — | — | — | |
| ROA | -12914.4% | -109.1% | -134.1% | -1508.5% | -7207.8% | -9.3% | -0.8% | -1.6% | -0.8% | -0.3% | -0.4% |
| — | -1073.8% | -17374.7% | -93093.4% | -935740.4% | -2768.4% | -74.8% | — | — | — | — | |
| ROIC | — | — | — | — | — | -40.3% | -0.7% | -1.3% | -0.6% | -0.2% | — |
| — | — | — | — | — | -16193.2% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 7.1% YoY to 0.17x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 1.01 | 0.11 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.09 | 0.17 | 0.09 | 0.22 | 0.09 | 0.19 | 0.06 | 0.02 | 0.09 | 0.80 | 1.92 |
| — | -7.1% | +44.4% | +790.0% | +1.4% | -76.7% | -96.6% | — | — | — | — | |
| Quick Ratio | 0.09 | 0.17 | 0.09 | 0.22 | 0.09 | 0.19 | 0.06 | 0.02 | 0.09 | 0.80 | 1.92 |
| — | -8.5% | +44.4% | +790.0% | +1.4% | -76.7% | -96.6% | — | — | — | — | |
| Interest Coverage | -3.46 | -0.77 | -1.52 | -53.66 | -2.82 | -28.56 | -0.47 | — | -8.51 | — | — |
| — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 10 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonAspire Biopharma Holdings, Inc.'s current P/E is -5.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Aspire Biopharma Holdings, Inc.'s business trajectory between earnings reports.